Pharma BD Deal Intelligence
A $1B asset purchase that gave ICU Medical a complete IV therapy portfolio by folding in Pfizer's Hospira Infusion Systems pumps, consumables, and solutions business. Integration proved costly and prolonged, though—$72.2M in 2019 alone—and recurring FDA Class I recalls over pump battery defects left shareholder returns badly lagging the market.
Strategically sound consolidation that delivered scale but was dragged down for years by integration costs, quality problems, and weak shareholder returns
Full analysis, sources & comparables →BioPharma Dive characterized the transaction as Pfizer continuing its trend of shedding non-core assets, with the Hospira Infusion Systems carve-out fitting a…
Value-creating and risk mitigated deal structure... will create a leading pure-play infusion therapy company, with estimated pro forma combined revenues of…
MassDevice noted the price was adjusted down to ~$900M from the original $1B due to HIS performance softness pre-close, but ICU Medical still emerged as a…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
ICU Medical agreed to acquire Pfizer's Hospira Infusion Systems business (IV pumps, solutions, devices) for $1B in cash and stock: $600M cash plus $400M in newly issued ICU Medical shares (giving Pfizer a 16.4% stake). Combined company pro forma revenue ~$1.45B. Final consideration adjusted to ~$900M for performance changes. Closed February 6, 2017.
Strategically sound consolidation that delivered scale but was dragged down for years by integration costs, quality problems, and weak shareholder returns
Assessment window: 5yr post-close.
$1.4B Pro forma combined revenue ICU Medical + HIS (TTM as of June 2016)
IV infusion therapy is the delivery of fluids, medications, and nutrition directly into the bloodstream via pumps, sets, and IV solutions. It is core hospital plumbing — used across virtually every inpatient setting from oncology and ICU to general medicine — making it a scale-and-safety business rather than a disease-targeted franchise.
The US hospital IV infusion market in 2016-17 was an oligopoly anchored by three scaled competitors plus specialty players. Baxter International was the dominant IV solutions and pumps competitor with strong saline/fluids manufacturing position (further consolidated post-Hurricane Maria supply disruptions in 2017). BD/CareFusion (post-2015 BD acquisition of CareFusion) led the smart-pump segment with Alaris. B. Braun Medical held meaningful share in solutions and pumps with Outlook/Infusomat platforms. Smiths Medical and Fresenius Kabi competed in specialty segments. Pre-deal, Hospira Infusion Systems (Plum, Symbiq, LifeCare PCA pumps plus IV solutions) was a top-three player but was strategically non-core to Pfizer post the 2015 Hospira acquisition, where Pfizer's interest was the biosimilars and sterile injectables franchises. ICU Medical brought IV-set and connector dominance (CLAVE needleless connector franchise) but lacked pumps and solutions scale. The deal made ICU Medical a vertically integrated pure-play infusion company at ~$1.45B pro forma revenue, large enough to compete head-to-head with Baxter and BD/CareFusion. Pfizer retained a 16.4% stake plus board rights — a vote of confidence rather than a clean exit. The price was later adjusted down to ~$900M reflecting HIS's pre-close performance softness, particularly Symbiq pump issues that triggered FDA Class I recalls. Source: https://www.fiercebiotech.com/medical-devices/pfizer-offloads-hospira-to-icu-medical-for-1b
| Deal | Year | Value | Outcome |
|---|---|---|---|
| ICU Medical, Inc. / Pfizer Inc. (Hospira Infusion Systems business) (this deal) | 2016 | $1.0B | 52 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2016 deals · Other deals